Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Gyre Therapeutics (GYRE) Shares Outstanding (Weighted Average) (2016 - 2025)

Gyre Therapeutics (GYRE) has disclosed Shares Outstanding (Weighted Average) for 14 consecutive years, with $37.8 million as the latest value for Q3 2023.

  • On a quarterly basis, Shares Outstanding (Weighted Average) rose 20.2% to $37.8 million in Q3 2023 year-over-year; TTM through Sep 2023 was $37.8 million, a 20.2% increase, with the full-year FY2022 number at $31.5 million, up 2.95% from a year prior.
  • Shares Outstanding (Weighted Average) was $37.8 million for Q3 2023 at Gyre Therapeutics, roughly flat from $37.8 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $37.8 million in Q3 2023 to a low of $12.0 million in Q1 2019.
  • A 5-year average of $26.2 million and a median of $31.0 million in 2021 define the central range for Shares Outstanding (Weighted Average).
  • Peak YoY movement for Shares Outstanding (Weighted Average): increased 0.32% in 2019, then skyrocketed 94.52% in 2021.
  • Gyre Therapeutics' Shares Outstanding (Weighted Average) stood at $12.0 million in 2019, then surged by 59.53% to $19.2 million in 2020, then skyrocketed by 59.76% to $30.6 million in 2021, then rose by 2.95% to $31.5 million in 2022, then increased by 19.97% to $37.8 million in 2023.
  • Per Business Quant, the three most recent readings for GYRE's Shares Outstanding (Weighted Average) are $37.8 million (Q3 2023), $37.8 million (Q2 2023), and $37.8 million (Q1 2023).